Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Accounts Payables (2017 - 2025)

Cue Biopharma (CUE) has disclosed Accounts Payables for 9 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 39.85% to $3.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.9 million through Dec 2025, up 39.85% year-over-year, with the annual reading at $3.9 million for FY2025, 39.85% up from the prior year.
  • Accounts Payables hit $3.9 million in Q4 2025 for Cue Biopharma, up from $2.3 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $6.5 million in Q3 2024 to a low of $1.6 million in Q2 2022.
  • Historically, Accounts Payables has averaged $3.0 million across 5 years, with a median of $2.7 million in 2022.
  • Biggest five-year swings in Accounts Payables: soared 161.05% in 2024 and later plummeted 63.73% in 2025.
  • Year by year, Accounts Payables stood at $2.6 million in 2021, then grew by 5.42% to $2.7 million in 2022, then increased by 28.19% to $3.5 million in 2023, then fell by 19.37% to $2.8 million in 2024, then soared by 39.85% to $3.9 million in 2025.
  • Business Quant data shows Accounts Payables for CUE at $3.9 million in Q4 2025, $2.3 million in Q3 2025, and $3.6 million in Q2 2025.